Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4163 Target Snapshot

Toll-like receptor 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
746Compounds
148Assays
0Approved Drugs
403.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Toll-like receptor 2 shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O60603. Start with COVID-19, then reuse UniProt O60603 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt O60603 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
COVID-19

Toll-like receptor 2 shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include VB-201. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Toll-like receptor 2 as ChEMBL target CHEMBL4163, mapped to UniProt O60603. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Toll-like receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4163
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O60603
Toll-like receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Toll-like receptor 2 is the right protein anchor across sources, using UniProt O60603 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameToll-like receptor 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO60603
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelToll-like receptor 2
UniProt AccessionO60603
Component TypeProtein
Sequence Length784 aa

Toll-like receptor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Toll-like receptor 2, mapped to UniProt O60603. Sequence length is 784 aa.

Mapped IDO60603
Review nameToll-like receptor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Toll-like receptor 2 shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block.

Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugVB-201
Clinical signal Phase II
psoriasis
1 linked drug · 1 direct · 1 efficacy
Linked drugVB-201
Clinical signal Phase II
ulcerative colitis
1 linked drug · 1 direct · 1 efficacy
Linked drugVB-201
Clinical signal Phase I
antineoplastic agent
1 linked drug · 1 direct · 1 efficacy
Linked drugTOMARALIMAB
Clinical signal Phase I
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugTOMARALIMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include VB-201. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50103.0
KI8.0
EC50289.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4472879 9.96 EC50 0.11 Preclinical
CHEMBL5575324 9.94 EC50 0.116 Preclinical
CHEMBL1923557 9.59 EC50 0.26 Preclinical
CHEMBL4552043 9.55 EC50 0.281 Preclinical
CHEMBL4756806 9.55 EC50 0.28 Preclinical
CHEMBL4442356 9.52 EC50 0.304 Preclinical
CHEMBL4759425 9.52 EC50 0.3 Preclinical
CHEMBL4546202 9.42 EC50 0.383 Preclinical
CHEMBL4791879 9.42 EC50 0.38 Preclinical
CHEMBL1923536 9.35 EC50 0.45 Preclinical
Distribution

pChEMBL Value Distribution

74
5.0
59
5.5
45
6.0
34
6.5
25
7.0
16
7.5
14
8.0
7
8.5
10
9.0
7
9.5
pChEMBL
Assay Landscape

Assay Landscape

148
Total Assays
269
Tested Compounds
2
Assay Types
Binding — 125 assays, 269 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 112 205 6.0
single protein format 10 32 6.4
assay format 2 32 5.8
tissue-based format 1 0 —
Functional — 23 assays, 43 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 22 42 7.5
assay format 1 1 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine